Welcome to our dedicated page for Bruker Corporation news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker Corporation stock.
Bruker Corporation (symbol: BRKR) stands as a global leader in analytical instrumentation. With over fifty years of innovation, Bruker aims to provide top-tier technological solutions for various analytical tasks. Headquartered in Massachusetts, USA, Bruker employs more than 6,500 individuals across 90 locations worldwide.
The company's operations are categorized into four main segments:
- BSI BioSpin: Specializes in magnetic resonance technologies, including NMR, EPR, and preclinical MRI systems.
- BSI CALID: Focuses on mass spectrometry, chromatography, molecular spectroscopy, and in vitro diagnostics.
- BSI Nano: Offers solutions in X-ray diffraction, elemental analysis, atomic force microscopy, and surface and dimensional metrology.
- Bruker Energy & Supercon Technologies (BEST): Provides superconducting materials and devices for energy, science, and healthcare sectors.
Bruker demonstrates a strong commitment to research and development, continuously expanding its suite of products and maintaining a robust installed base globally. The company’s dedication to quality and reliability is reflected in its significant presence in the Asia Pacific region, which accounts for the largest share of its revenue.
Recent achievements include advancements in mass spectrometry and collaborations with leading pharmaceutical and biotechnology companies. Bruker's technologies are vital for quality assurance in industrial production processes, supporting customers in ensuring precision and reliability.
Bruker Corporation is not just a manufacturer but a partner in innovation, helping scientists and researchers address complex analytical challenges with integrity and cutting-edge technology.
Bruker recently showcased its innovative Ascend Evo 1.0 GHz NMR magnet at the Experimental Nuclear Magnetic Resonance Conference, designed to operate at 4.2 Kelvin for structural biology in standard labs. This new technology boasts a significant reduction in liquid helium consumption by threefold, enhancing accessibility for researchers. Additionally, Bruker introduced the Heliosmart Recovery system which enables the collection of helium gas boil-off, achieving recovery rates of 80%-85%. The company continues to offer services like LabScape Remote Monitoring for effective management of NMR magnets.
Bruker Corporation (Nasdaq: BRKR) recently introduced advancements in its MALDI Biotyper® platform and launched new multiplex PCR assays at the 32nd European Congress of Clinical Microbiology & Infectious Diseases. Key offerings include the FluoroType® Mycobacteria PCR assay, which differentiates 32 mycobacteria species, and the FluoroType® STI PCR assay, which detects seven major STI pathogens. These innovations enhance Bruker's portfolio in infectious disease diagnostics, leveraging its LiquidArray® technology for improved accuracy and speed in clinical settings.
Bruker Corporation (NASDAQ: BRKR) will report its first quarter 2022 financial results on May 4, 2022, before market opening. A conference call and webcast will take place at 8:30 a.m. Eastern Time to discuss these results and current business trends. Investors can access the webcast through Bruker's investor relations website or via telephone. A replay will be available starting one hour after the call until June 4, 2022. Bruker continues to support scientific innovation and diagnostics in various research fields.
Bruker Corporation (Nasdaq: BRKR) has unveiled innovative technologies at the AACR Annual Meeting 2022, focusing on spatial multiomics and single-cell proteomics for cancer research. Key launches include the MALDI HiPLEX-IHC tissue imaging solution, which integrates protein mapping with small molecule imaging, and the CellScape™ platform for high-precision spatial proteomics. The timsTOF fleX platform can identify over 13,000 proteins, advancing the capabilities in cancer profiling. These advancements position Bruker to enhance cancer research methodologies significantly.
Bruker Corporation (BRKR) has successfully acquired IonSense Inc., a leader in ambient DART ionization technology. This acquisition aims to enhance the development of DART ionization sources and expand applications in food analysis and forensics. IonSense will leverage Bruker's financial investments to accelerate their product development and reach a broader market. The DART technology uniquely analyzes solids, liquids, and gases without prior chromatography, offering faster sample identification. This merger positions Bruker to further tap into the $4B mass spectrometry marketplace.
Bruker Corporation (NASDAQ: BRKR) has announced the acquisition of Optimal Industrial Automation and Technologies, enhancing its role in pharmaceutical process analytical technology (PAT) and manufacturing automation. The acquisition is expected to complement Bruker's existing offerings in high-value NMR and mass spectrometry, positioning them as a key software provider for the biopharma sector. While financial specifics were not disclosed, Optimal's 2022 revenue is projected at $10 million, with anticipated positive impacts on Bruker's revenue and operating margins.
Bruker Corporation (Nasdaq: BRKR) has unveiled enhanced capabilities for proteomic and epiproteomic analysis using its innovative TIMScore™ algorithm integrated into the PaSER 2022 system. This new technology allows for the identification of over 8000 protein groups in just 35 minutes while improving phosphopeptide identification by more than 25%. With access to ultra-deep libraries of over 13,000 protein groups, the TIMScore™ algorithm enhances peptide confidence and coverage, supporting high-throughput translational proteomics.
Bruker Corporation (NASDAQ: BRKR) has announced the appointment of Philip Ma, Ph.D., to its Board of Directors, effective April 1, 2022. Dr. Ma is the CEO and founder of PrognomiQ and has significant experience in life sciences, particularly in multiomics and cancer diagnostics. His previous roles include leadership positions at Biogen and McKinsey & Company. The company aims to leverage his expertise to advance its Project Accelerate 2.0 initiatives, which focus on enhancing life science and clinical research tools.
Bruker Corporation (NASDAQ: BRKR) announced enhanced capabilities for its Fourier 80 benchtop FT-NMR spectrometer, now featuring an Adjustable Temperature option for samples between 25°C to 60°C. This upgrade expands applications in pharmaceutical and food analysis, improving synthesis and process control. The introduction of the RxnLab™ solution offers temperature-controlled monitoring of reactions, while the Olive Oil-Profiling™ 1.0 solution supports olive oil authenticity analysis. The enhancements aim to elevate research capabilities in various analytical laboratories.
Canopy Biosciences, a Bruker Company, launched the CellScape™ System, enhancing ChipCytometry technology for high-plex spatial proteomics. This new benchtop system improves automation, optical performance, and throughput, enabling researchers to analyze millions of cells with single-cell resolution. Since the 2020 acquisition by Bruker, Canopy has advanced its capabilities, setting a new standard in spatial biology research. The CellScape™ is designed for large-scale clinical studies and is compatible with standard fluorescently labeled antibodies, fostering streamlined workflows in immunology and other fields.
FAQ
What is the current stock price of Bruker Corporation (BRKR)?
What is the market cap of Bruker Corporation (BRKR)?
What does Bruker Corporation specialize in?
How is Bruker Corporation structured?
Where does Bruker generate most of its revenue?
How many employees does Bruker Corporation have?
What industries does Bruker serve?
What recent advancements has Bruker made?
What is BSI BioSpin known for?
Why are Bruker's technologies important in industrial production?
What is the BEST segment of Bruker Corporation?
How does Bruker Corporation contribute to scientific research?
